Nov 16, 2017
FDA backs Roche's Gazyva in first-line follicular ... - https://goo.gl/hhP5NN - #Backs, #FDA, #Firstline, #Follicular, #Gazyva, #Nutrition, #Roche039S
seen from Germany
seen from United States
seen from China
seen from Israel
seen from China
seen from United Kingdom
seen from Hong Kong SAR China
seen from Israel
seen from United States
seen from China
seen from United States
seen from Pakistan
seen from Singapore
seen from China
seen from China
seen from Germany
seen from China
seen from China
seen from Germany
seen from Italy
FDA backs Roche's Gazyva in first-line follicular ... - https://goo.gl/hhP5NN - #Backs, #FDA, #Firstline, #Follicular, #Gazyva, #Nutrition, #Roche039S
Roche updates on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma
Roche updates on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma
18 July 2016
Roche has announced that the phase III GOYA study that evaluates Gazyva®/Gazyvaro® (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint to significantly reduce the risk of disease worsening or death compared to MabThera/Rituxan (rituximab) plus CHOP chemotherapy (R-CHOP). It was…
View On WordPress
Roche announces positive results for Gazyva in phase III study
Roche announces positive results for Gazyva in phase III study
Roche announces positive results for Gazyva in phase III study ZURICH (Reuters) – Roche Holding AG said on Friday its drug Gazyva showed superior progression-free survival compared to Mabthera/Rituxan in people with previously untreated follicular lymphoma in the pivotal phase III Gallium study that met is primary endpoint early.
View On WordPress